Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

Fig. 2

Correlations of change in FABP4 level with parameters. a–c Fatty acid-binding protein 4 (FABP4) level at baseline (a), change in waist circumference (b) and change in creatinine level (c) were plotted against change in FABP4 level in each subject (n = 307). Closed circles and solid regression line: anagliptin treatment group (n = 148), open circles and broken regression line: sitagliptin treatment group (n = 159)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840